Drug intelligence / Profile preview

SCT510A

Development stage: Phase 3
Lead developer: Sinocelltech
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravitreal

Overview

SCT510A is a bevacizumab biosimilar developed by Sinocelltech. It is a recombinant humanized monoclonal antibody that targets vascular endothelial growth factor A (VEGF-A), functioning as an angiogenesis inhibitor. By binding to VEGF-A, it prevents the formation of new blood vessels that supply tumors with oxygen and nutrients, potentially slowing tumor growth. SCT510A is being investigated for the treatment of wet age-related macular degeneration (wAMD) via intravitreal injection.

Targets

VEGFA (Vascular endothelial growth factor A)

Beyond the preview

Go deeper on SCT510A.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SCT510A.

Explore the full profile